The Traderszone Network

Published in TZ Latest News 9 August, 2014 by The TZ Newswire Staff

Update: Oragenics Earnings – Slow Q2 Revenue Growth Supports Restructuring

By Trevor Lowenthal:

In April I wrote a PRO article with a bull thesis stating that Oragenics’ (NYSEMKT:OGEN) development of the lantibiotic Mu1140-S, using its patented organic chemistry synthesis platform, DPOLT (Differentially Protected Orthogonal Lanthionine Technology), could u

read more